TRACON Pharmaceuticals, Inc.
TCON · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 99.9% | – | 96% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -57.2% | – | -8,188.7% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -29.8% | – | -8,302.3% | – |
| EPS Diluted | -2.19 | -28.02 | -33.3 | -38.57 |
| % Growth | 92.2% | 15.9% | 13.7% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |